A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life
CH Choi, SY Jo, HJ Park, SK Chang… - Journal of Clinical …, 2011 - journals.lww.com
Background Probiotics confer health benefits to the host. However, its clinical effect on
irritable bowel syndrome (IBS) is controversial. Aims This study was aimed to evaluate the
effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with
diarrhea-predominant IBS or mixed-type IBS. Methods Sixty-seven patients with IBS were
randomized either to receive S. boulardii at 2× 10 11 live cells as a daily dose (n= 34), or
placebo (n= 33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the …
irritable bowel syndrome (IBS) is controversial. Aims This study was aimed to evaluate the
effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with
diarrhea-predominant IBS or mixed-type IBS. Methods Sixty-seven patients with IBS were
randomized either to receive S. boulardii at 2× 10 11 live cells as a daily dose (n= 34), or
placebo (n= 33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the …
A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life.
CCH Choi ChangHwan, JSY Jo SunYoung… - 2011 - cabidigitallibrary.org
Background: Probiotics confer health benefits to the host. However, its clinical effect on
irritable bowel syndrome (IBS) is controversial. Aims: This study was aimed to evaluate the
effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with
diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were
randomized either to receive S. boulardii at 2× 1011 live cells as a daily dose (n= 34), or
placebo (n= 33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the …
irritable bowel syndrome (IBS) is controversial. Aims: This study was aimed to evaluate the
effects of Saccharomyces boulardii on quality of life (QOL) and symptoms in patients with
diarrhea-predominant IBS or mixed-type IBS. Methods: Sixty-seven patients with IBS were
randomized either to receive S. boulardii at 2× 1011 live cells as a daily dose (n= 34), or
placebo (n= 33) for 4 weeks. IBS-QOL was assessed at the beginning and end of the …